Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study

Tonstad, S · 2003 · European Heart Journal

Abstract

AIMS: To investigate the safety and efficacy of bupropion sustained release (bupropion SR) in promoting abstinence from smoking in subjects with cardiovascular disease (CVD). METHODS: Six hundred twenty-nine subjects with CVD who smoked >/=10 cigarettes/day were randomised in a double-blind, multicentre study to receive bupropion SR (150 mg twice daily) or placebo for 7 weeks, with a follow-up of 52 weeks. Primary efficacy endpoint: continuous abstinence from smoking from weeks 4 to 7. Secondary endpoints: continuous abstinence (weeks 4-12, 4-26 and 4-52) and weekly point prevalence abstinence. All participants received brief motivational support. Safety was evaluated throughout the study. RESULTS: Continuous smoking abstinence rates from weeks 4 to 7 were significantly higher in subjects receiving bupropion SR compared with placebo (43 vs. 19%, odds ratio [OR]=3.27, 95% confidence interval [CI] 2.24-4.84; P<0.001). Continuous abstinence rates from weeks 4 to 26 and 4 to 52 continued to be more than double for bupropion SR compared with placebo (27 vs. 11%; 22 vs. 9%, P<0.001). Weekly point prevalence abstinence was significantly higher for participants who received bupropion SR compared with placebo at weeks 3, 7, 26 and 52 (P<0.001). In both groups, there were no clinically significant changes in blood pressure and heart rate throughout the treatment phase. Overall, 6% of the participants (n=36) discontinued study medication due to an adverse event (bupropion SR, n=17; placebo, n=19). CONCLUSIONS: After 7 weeks of bupropion SR treatment, more than twice as many smokers with CVD had quit smoking at 1 year compared with placebo. The safety profile of bupropion SR was similar to that previously observed in general smoking populations.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0195-668x(03)00003-4

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

See all 246

Metadata

Authors
Tonstad, S.
Affiliations
Oslo University Hospital (NO)
Corresponding author
Tonstad, S
Venue
European Heart Journal
Published
2003-05
Volume
24
Issue
10
Pages
946-955
ISSN
0195-668X (ISSN-L)
OpenAlex
W2100116850
Cited by
246
References
25
Citations by year
2026: 4 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 2 · 2021: 7 · 2020: 4 · 2019: 6 · 2018: 6 · 2017: 8 · 2016: 10 · 2015: 7 · 2014: 13 · 2013: 16 · 2012: 14
FWCI
9.20
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
  • reroDoc Digital Library (submittedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
bupropion sustained release, smoking cessation, cardiovascular disease, smoking abstinence, nicotine dependence, pharmacotherapy, blood pressure, heart rate, adverse events
MeSH terms
Smoking Prevention, Adult, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Male, Middle Aged, Prospective Studies, Smoking, Smoking Cessation, Bupropion, Treatment Outcome, Dopamine Uptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. https://app.cochat.ai/papers/10.1016/s0195-668x(03)00003-4
The paper
Tonstad, S. (2003). Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. European Heart Journal. https://doi.org/10.1016/s0195-668x(03)00003-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.